Latest Regulus Therapeutics Inc. Stories

CARLSBAD, Calif., March 1 /PRNewswire-FirstCall/ -- Reports Second Consecutive Year of Pro Forma Net Income Achieves All 2009 Financial Guidance MetricsConference Call Webcast Monday, March 1, 8:30 a.m. EST at www.isispharm.comIsis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2...

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states,...

CARLSBAD, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter ended September 30, 2009. For the quarter, Isis reported a net loss of $3.4 million and a net operating loss of $6.9 million. In addition, for the first nine months of 2009, Isis reported net income of $170.3 million and a net operating loss of $6.1 million. Isis is confident that it will meet its 2009 financial guidance of more than $145...

CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with...

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669,000 of pro forma net income for the quarter ended June 30, 2009, a significant improvement over the same period in 2008. Isis also reported a pro forma net operating loss of $1.3 million for the second quarter compared...

- Conference Call Webcast Thursday, May 7, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., May 7 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended March 31, 2009. Primarily as a result of the $171.8 million gain that Isis recognized from selling its Ibis Biosciences subsidiary to Abbott Molecular Inc. (AMI), Isis finished the first quarter of 2009 with pro forma net income of $173.0 million. Isis also...

- Exceeds 2008 Projections for Net Operating Income and Year-End Cash - Achieves 2008 Positive Pro Forma Net Operating Income and Net Income - Conference Call Webcast Wednesday, February 25, 8:30 a.m. EST at www.isispharm.com CARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2008 financial results and business highlights. Isis exceeded its 2008 financial guidance by ending 2008 with positive pro forma net income of $3.1...